Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

surfacepharma.com

Founded Year

2017

Stage

Series B | Alive

Total Raised

$45M

Last Raised

$25M | 1 yr ago

About Surface Ophthalmics

Surface Pharmaceuticals is a drug development company working on treatments for dry eye and blepharitis. Surface's pipeline includes eye drops SURF-100 and SURF-200, which combine the generic medications mycophenolic acid and betamethasone, respectively, with Imprimis' delivery vehicle, Klarity, a topical opthalmic gel or solution. The company's third drug, SURF-300, combines the antibiotic doxycycline and omega-3 in an oral capsule.

Surface Ophthalmics Headquarters Location

5000 Hopyard Rd

Pleasanton, California, 94588,

United States

858-405-4448

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Surface Ophthalmics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Surface Ophthalmics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Surface Ophthalmics Patents

Surface Ophthalmics has filed 4 patents.

The 3 most popular patent topics include:

  • H1 receptor antagonists
  • Amines
  • Autoimmune diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/4/2019

Glucocorticoids, Pregnanes, Fluoroarenes, H1 receptor antagonists, Corticosteroid esters

Application

Application Date

12/4/2019

Grant Date

Title

Related Topics

Glucocorticoids, Pregnanes, Fluoroarenes, H1 receptor antagonists, Corticosteroid esters

Status

Application

Latest Surface Ophthalmics News

Surface Ophthalmics: Raises $25M in Funding

Jul 26, 2021

Surface Ophthalmics Raises $25M in Funding Surface Ophthalmics , a Pleasanton CA-based pharmaceutical company, raised $25M in funding Investors included both new and existing investors made up of institutional, healthcare-focused, and other accredited investors The company intends to use the funds to advance its clinical programs in ocular diseases The company is a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases The company will be positioned to begin enrolling patients in Phase III clinical trials, targeting FDA approval These programs utilize Klarity® as the delivery vehicle, which is designed to enhance patient comfort as well as protect and rehabilitate the ocular surface Tags:

  • When was Surface Ophthalmics founded?

    Surface Ophthalmics was founded in 2017.

  • Where is Surface Ophthalmics's headquarters?

    Surface Ophthalmics's headquarters is located at 5000 Hopyard Rd, Pleasanton.

  • What is Surface Ophthalmics's latest funding round?

    Surface Ophthalmics's latest funding round is Series B.

  • How much did Surface Ophthalmics raise?

    Surface Ophthalmics raised a total of $45M.

  • Who are the investors of Surface Ophthalmics?

    Investors of Surface Ophthalmics include Visionary Venture Fund, Flying L Partners and Imprimis Pharmaceuticals.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.